Photocure ASA - Positive Allumera Trial Results

Published: 4 February 2011Medical InformationProduct Announcements

Photocure Announces Positive Allumera(TM) Trial Results For Delivering Significant Skin Appearance Improvements


Oslo, Norway, 4 February, 2011 - Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera(TM), a breakthrough cosmetic treatment formulated to improve the skin's appearance.

The RevitAll study was performed with a standard cosmetic protocol and designed to confirm if treatment with Allumera(TM) improves skin appearance, when compared to exposure by light alone. The study also looked into longevity of results.

This controlled, prospective study enrolled 120 women to receive three treatments, four weeks apart. The total duration of the study was five months. Half the study participants received Allumera(TM) plus light, while the remaining received light alone (control group). Participants were monitored for three months following the last treatment to evaluate which effects were long-lasting. The study evaluations included both objective and subjective assessments. The objective assessments included measurement of appearance of pores, skin firmness/elasticity, skin tone (radiance/luminosity), skin surface topography and tolerability.


At the five month evaluation, participants who received Allumera(TM) for one hour followed by exposure to light, showed a significant 44% reduction in the appearance of pores (p<0.001), when compared to baseline, and the difference between the two groups was statistically significant (p=0.002). A statistically significant improvement (p<0.0001) in skin firmness and suppleness was also observed for the Allumera group when compared to the control group. A 35% improvement in the appearance of skin tone (p<0.05) was also found, but this, however, was not statistically significant when compared to the control group.

"The results from our RevitAll study provide a solid foundation for our efforts to commercialize Allumera(TM)," said Kjetil Hestdal, M.D. Ph.D., President and Chief Executive Officer of Photocure. "It is a significant milestone for our Photocure Technology(TM) and provides validation for for our technology in cosmetic dermatology aimed at improving the skin's appearance. The launch of Allumera(TM) will be a major step forward in establishing Photocure's US business."

In addition to the objective statistical measurements, Allumera(TM) demonstrated significant subjective feedback from trial participants including confirmation of:

·         Revitalized, younger-looking, clearer and more beautiful skin
·         Reduced appearance of crows feet, dark circles, fine lines and wrinkles
·         Firmer appearance of skin
·         Improvement in the feeling of moisture, smoothness and overall skin texture

"Allumera(TM) is an exciting, effective new option to achieve a radiant and supple facial appearance, with minimal downtime," said Mitchel P. Goldman, MD, Volunteer Clinical Professor of Dermatology at University of California, San Diego. "Allumera(TM) will be a valuable new product filling a gap for our patients looking to discreetly and non-invasively minimize the appearance of wrinkles, dark circles and pores."

Photocure is on track to launch Allumera in the US during second quarter 2011.

For further information, please contact:


President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email:

CFO Christian Fekete

Tel: + 47 916 42 938, Email:

Capital MS&L
Mary Clark, Justine Lamond and Hollie Vile
Tel: +44 (0)20 7307 5337, Email:



About Allumera(TM)
Allumera(TM) is a topical cosmetic cream specially formulated to improve the overall appearance of skin. When used with light, Allumera(TM) works with the body's capabilities to visibly reduce many unwanted skin characteristics, such as the appearance of fine lines, dark circles, crow's feet and enlarged pores. Photocure's Allumera(TM) is a unique skincare formula applied by a healthcare professional and has been found to improve the overall appearance of skin, leaving a more radiant, firmer and healthier complexion.


About Photocure ASA
Photocure ASA is a worldwide leader in photodynamic therapy. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix® is approved in the European Union and the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is very selective, targeting only diseased cells and preserving healthy tissue. Photocure Technology(TM) is being tested for new products and indications including acne, improving the appearance of skin (Allumera(TM)), diagnosing colon cancer (Lumacan(TM) which is outlicensed to Salix Pharmaceuticals) and the treatment of pre-malignant cervical lesions (Cevira®).

Photocure®, Cevira® and Hexvix® are registered trademarks of Photocure ASA.

Photocure, Inc. is the marketing and sales subsidiary of Photocure ASA in the US. It is located in Princeton, NJ. 

For more information about Photocure, visit our website at

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events